These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20919529)

  • 1. The role of PET scanning in pancreatic cancer.
    Serrano OK; Chaudhry MA; Leach SD
    Adv Surg; 2010; 44():313-25. PubMed ID: 20919529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.
    Rose DM; Delbeke D; Beauchamp RD; Chapman WC; Sandler MP; Sharp KW; Richards WO; Wright JK; Frexes ME; Pinson CW; Leach SD
    Ann Surg; 1999 May; 229(5):729-37; discussion 737-8. PubMed ID: 10235532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
    Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
    J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
    Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
    Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer.
    Kim MJ; Lee KH; Lee KT; Lee JK; Ku BH; Oh CR; Heo JS; Choi SH; Choi DW
    Pancreas; 2012 Aug; 41(6):897-903. PubMed ID: 22699202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study.
    Sperti C; Pasquali C; Decet G; Chierichetti F; Liessi G; Pedrazzoli S
    J Gastrointest Surg; 2005 Jan; 9(1):22-8; discussion 28-9. PubMed ID: 15623441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.
    Yeh R; Dercle L; Garg I; Wang ZJ; Hough DM; Goenka AH
    Abdom Radiol (NY); 2018 Feb; 43(2):415-434. PubMed ID: 29143875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer.
    Pergolini I; Crippa S; Salgarello M; Belfiori G; Partelli S; Ruffo G; Pucci A; Zamboni G; Falconi M
    Dig Liver Dis; 2018 Jan; 50(1):84-90. PubMed ID: 29017830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer.
    Lytras D; Connor S; Bosonnet L; Jayan R; Evans J; Hughes M; Garvey CJ; Ghaneh P; Sutton R; Vinjamuri S; Neoptolemos JP
    Dig Surg; 2005; 22(1-2):55-61; discussion 62. PubMed ID: 15838173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET and PET/CT for pancreatic malignancies.
    Delbeke D; Martin WH
    Surg Oncol Clin N Am; 2010 Apr; 19(2):235-54. PubMed ID: 20159513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [18FDG-PET imaging of pancreatic adenocarcinoma].
    Daenen F; Hustinx R; Belhocine T; Focan C; Honoré P; Rigo P
    Rev Med Liege; 2000 Feb; 55(2):89-94. PubMed ID: 10769575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinically determined type of 18F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer.
    Chong JU; Hwang HK; Lee JH; Yun M; Kang CM; Lee WJ
    PLoS One; 2017; 12(2):e0172606. PubMed ID: 28235029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.
    Tomimaru Y; Takeda Y; Tatsumi M; Kim T; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Kitagawa T; Nagano H; Umeshita K; Wakasa K; Doki Y; Mori M
    Oncol Rep; 2010 Sep; 24(3):613-20. PubMed ID: 20664965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. THE USE OF 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY TO ASSESS CLINICAL OUTCOMES OF PATIENTS WITH BORDERLINE RESECTABLE PANCREATIC CANCER.
    Durmus A; Yilmaz A; Malya F; Ozturk G; Bektasoglu H; Ertugrul G; Karyagar S; Karatepe O
    Georgian Med News; 2016 Apr; (253):26-9. PubMed ID: 27249430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is positron emission tomography using 18F-fluorodeoxyglucose and 11C-acetate valuable in diagnosing indeterminate pancreatic masses?
    Rasmussen I; Sörensen J; Långström B; Haglund U
    Scand J Surg; 2004; 93(3):191-7. PubMed ID: 15544073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms.
    Farma JM; Santillan AA; Melis M; Walters J; Belinc D; Chen DT; Eikman EA; Malafa M
    Ann Surg Oncol; 2008 Sep; 15(9):2465-71. PubMed ID: 18551347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of pancreatic carcinoma with FDG PET.
    Jadvar H; Fischman AJ
    Abdom Imaging; 2001; 26(3):254-9. PubMed ID: 11429948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.